Last reviewed · How we verify
AV-1451
At a glance
| Generic name | AV-1451 |
|---|---|
| Also known as | 7-(6-[18F]fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alzheimer's Disease Neuroimaging Initiative 4
- Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study (NA)
- Longitudinal Early-onset Alzheimer's Disease Study Protocol
- A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy (NA)
- UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy (PHASE1)
- Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
- Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
- Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AV-1451 CI brief — competitive landscape report
- AV-1451 updates RSS · CI watch RSS
- Mayo Clinic portfolio CI